Nanotech

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX-V: GRA and OTCQX: NNXPF) is pleased to announce that on October 27, 2020, it received a blanket purchase order from Martinrea International Inc. (" Martinrea ") (TSX: MRE) to supply graphene for fuel and brake lines for passenger vehicles produced by North American automotive Original Equipment Manufacturers (" OEM "). These graphene-enhanced products were tested and approved by OEMs and demonstrate significant lifetime improvements in comparison with existing solutions in the market. These parts will be supplied to OEMs by Martinrea within already-awarded multi-year fuel and brake line supply programs.

Soroush Nazarpour, President & CEO of NanoXplore, commented:

" A fter a long development process, I am very pleased that our graphene will be introduced to passenger vehicle programs in early 2021 . This is an important achievement for NanoXplore and its business, as entering into such applications and supplying world-class OEMs demand a high standard of quality. The t ransportation market is actively looking for sustainable , innovative, and cost -effective solutions and I am happy that our graphene addresses these needs. "

About NanoXplore Inc.

NanoXplore is a graphene company, a manufacturer and supplier of high-volume graphene powder for use in industrial markets. The company provides standard and custom graphene-enhanced plastic and composite products to various customers in transportation, packaging, electronics, and other industrial sectors. NanoXplore is headquartered in Montreal, Quebec with manufacturing facilities across Canada, the United States and Europe.

Forward-looking Statements

This press release contains forward-looking statements. All forward-looking statements are based on our beliefs as well as assumptions based on information available at the time the assumption was made and on management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors deemed appropriate in the circumstances. No assurance can be given that these assumptions and expectations will prove to be correct. Forward-looking statements are not facts, but only predications and can generally be identified by the use of statements that include phrases such as "anticipate", "believe", "continue", "could", "estimate", "foresee", "grow", "expect", "plan", "intend", "forecast", "future", "guidance", "may", "predict", "project", "should", "strategy", "target", "will" or similar expressions suggesting future outcomes .

Forward-looking information is not a guarantee of future performance and involves a number of risks and uncertainties. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause NanoXplore's actual results to differ materially from any projections of future results expressed or implied by such forward-looking information. Any forward-looking information is made as of the date hereof and, except as required by law, NanoXplore does not undertake any obligation to publicly update or revise such information to reflect new information, subsequent or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Soroush Nazarpour
President & CEO
NanoXplore Inc.
info@NanoXplore.ca

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform

Company restructuring and cost savings associated with NUV-422 program discontinuation to extend cash runway through 2028

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide

Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Top 6 Nanotechnology Uses

Top 6 Nanotechnology Uses

While there’s been plenty of focus on apps and cloud computing in the technology space, advances are also being made in hardware-focused sectors such as nanotechnology.

Nanotechnology uses include everything from safer food processing to more efficient drug-delivery systems to tiny transistors that allow for smaller, more powerful computer chips. Unsurprisingly, nanotechnology applications are set to grow significantly in the coming years. The global nanotechnology market is projected to reach US$70.7 billion by 2026, growing at a compound annual growth rate of 9.2 percent between 2020 and 2026.

Still, for investors just starting to look at nanotechnology stocks, it can be difficult to know where to begin as nanotechnology applications are so varied. As a starting point, here’s an overview of six of the top areas in which nanoscience and nanotechnologies are making a big difference today.

Keep reading...Show less

NanoXplore Announces Management and Board Changes

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) announces today that after more than eight years with NanoXplore, Luc Veilleux, CFO, will be departing the Company from his position on July 18, 2022 and will be joining VoltaXplore as CFO. He will remain with the Corporation until September 1, 2022 to ensure a smooth transition. Luc has over 25 years of executive management, financial and operational experience in manufacturing and mining industries. His previous roles include CFO of Mason Graphite, President of Maxi Canada, and CFO of Imerys Graphite and Carbon. Mr. Veilleux, with his work ethic and talent, made a major contribution to NanoXplore's development.

"On behalf of everyone at NanoXplore, I'd like to express my gratitude to Luc for his outstanding leadership, selfless partnership, and financial stewardship. Luc has played a crucial role in NanoXplore's success and growth by helping lay the solid foundation that supports the company's innovation, global presence and financial strength. I am looking forward to continue working with Luc in VoltaXplore" said Soroush Nazarpour, President and CEO, NanoXplore.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company's Phase 1 trial began enrolling patients 19 months ago in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose. Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

"We are committed to patient safety across all of our studies and to working collaboratively with the FDA to develop, as efficiently as possible, new medicines where existing therapies are inadequate," said David Hung, M.D., founder, president and chief executive officer of Nuvation Bio. "Based upon the recent development of uveitis as a potential safety signal, we will conduct an overall risk/benefit analysis of the NUV-422 program. Our goal is always to ensure that we deploy our resources on programs that have the highest probability of success and of generating value for patients and our investors. With $737.7 million in cash as of March 31, 2022, we are well positioned to continue developing all of our internal product candidates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×